Quantum Biopharma (QNTM) Competitors $18.45 +0.35 (+1.93%) Closing price 04:00 PM EasternExtended Trading$18.06 -0.40 (-2.14%) As of 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock QNTM vs. HRTX, AVIR, ZURA, TNXP, SGMT, VTYX, PRQR, TRDA, RENB, and CABAShould you be buying Quantum Biopharma stock or one of its competitors? The main competitors of Quantum Biopharma include Heron Therapeutics (HRTX), Atea Pharmaceuticals (AVIR), Zura Bio (ZURA), Tonix Pharmaceuticals (TNXP), Sagimet Biosciences (SGMT), Ventyx Biosciences (VTYX), ProQR Therapeutics (PRQR), Entrada Therapeutics (TRDA), Lunai Bioworks (RENB), and Cabaletta Bio (CABA). These companies are all part of the "pharmaceutical products" industry. Quantum Biopharma vs. Its Competitors Heron Therapeutics Atea Pharmaceuticals Zura Bio Tonix Pharmaceuticals Sagimet Biosciences Ventyx Biosciences ProQR Therapeutics Entrada Therapeutics Lunai Bioworks Cabaletta Bio Quantum Biopharma (NASDAQ:QNTM) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations. Is QNTM or HRTX more profitable? Quantum Biopharma has a net margin of 0.00% compared to Heron Therapeutics' net margin of -0.62%. Heron Therapeutics' return on equity of 0.00% beat Quantum Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Quantum BiopharmaN/A -270.22% -131.87% Heron Therapeutics -0.62%N/A -0.40% Do analysts prefer QNTM or HRTX? Heron Therapeutics has a consensus target price of $4.50, indicating a potential upside of 240.91%. Given Heron Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Heron Therapeutics is more favorable than Quantum Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Heron Therapeutics 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has stronger earnings and valuation, QNTM or HRTX? Heron Therapeutics has higher revenue and earnings than Quantum Biopharma. Heron Therapeutics is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuantum BiopharmaN/AN/A-$14.20M-$14.02-1.32Heron Therapeutics$144.29M1.68-$13.58M-$0.02-66.00 Which has more risk and volatility, QNTM or HRTX? Quantum Biopharma has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500. Does the media refer more to QNTM or HRTX? In the previous week, Quantum Biopharma had 8 more articles in the media than Heron Therapeutics. MarketBeat recorded 8 mentions for Quantum Biopharma and 0 mentions for Heron Therapeutics. Quantum Biopharma's average media sentiment score of 0.20 beat Heron Therapeutics' score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the media. Company Overall Sentiment Quantum Biopharma Neutral Heron Therapeutics Neutral Do insiders and institutionals believe in QNTM or HRTX? 1.2% of Quantum Biopharma shares are owned by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are owned by institutional investors. 8.5% of Quantum Biopharma shares are owned by insiders. Comparatively, 5.9% of Heron Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryHeron Therapeutics beats Quantum Biopharma on 10 of the 14 factors compared between the two stocks. Get Quantum Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for QNTM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QNTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QNTM vs. The Competition Export to ExcelMetricQuantum BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$69.07M$3.32B$6.06B$10.59BDividend YieldN/A2.28%5.52%4.66%P/E RatioN/A8.0358.3422.96Price / SalesN/A457.06602.84131.54Price / CashN/A46.6137.7361.25Price / Book4.069.9312.556.55Net Income-$14.20M-$52.59M$3.30B$277.26M7 Day Performance13.05%5.28%28,056.17%2.41%1 Month Performance17.52%12.54%28,977.34%9.26%1 Year Performance370.66%28.76%35,796.37%32.66% Quantum Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QNTMQuantum Biopharma0.5066 of 5 stars$18.45+1.9%N/A+354.8%$69.07MN/A0.00N/ANews CoverageGap UpHRTXHeron Therapeutics3.5663 of 5 stars$1.27-0.4%$4.50+255.7%-37.8%$231.89M$149.69M-63.25300Positive NewsAVIRAtea Pharmaceuticals1.8517 of 5 stars$2.90-0.9%$6.00+107.3%-16.3%$230.14MN/A-1.8070Positive NewsZURAZura Bio3.1855 of 5 stars$3.57+19.5%$11.60+224.7%+3.3%$230.11MN/A-5.063Analyst ForecastGap DownTNXPTonix Pharmaceuticals2.9544 of 5 stars$25.21+1.8%$70.00+177.7%+89.4%$221.87M$9.83M-0.6450SGMTSagimet Biosciences2.8269 of 5 stars$6.82-1.5%$25.67+276.6%+110.6%$220.81M$2M-3.718Analyst ForecastVTYXVentyx Biosciences1.6503 of 5 stars$3.16+4.1%$7.50+137.7%+67.3%$220.35MN/A-1.8430Gap UpPRQRProQR Therapeutics2.5 of 5 stars$2.11-3.9%$8.00+280.0%+19.7%$219.89M$20.46M-4.54180Positive NewsTRDAEntrada Therapeutics3.1532 of 5 stars$5.83-0.2%$25.67+340.3%-63.7%$219.82M$79.48M-3.25110RENBLunai Bioworks0.6053 of 5 stars$1.29+2.1%N/A-66.5%$218.77MN/A-1.6520Stock SplitGap DownCABACabaletta Bio2.7825 of 5 stars$2.34-1.8%$14.50+520.2%-45.1%$214.47MN/A-0.8750 Related Companies and Tools Related Companies Heron Therapeutics Alternatives Atea Pharmaceuticals Alternatives Zura Bio Alternatives Tonix Pharmaceuticals Alternatives Sagimet Biosciences Alternatives Ventyx Biosciences Alternatives ProQR Therapeutics Alternatives Entrada Therapeutics Alternatives Lunai Bioworks Alternatives Cabaletta Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QNTM) was last updated on 10/3/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredChina’s message to TrumpPorter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quantum Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quantum Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free QNTM Stock Alerts